Molecular testing has become more accessible for Manitobans living with cancer after physicians saw its importance in providing patients with the best possible treatment, based on their genetic profile. CCMB researchers conducted a study to test the effectiveness of a new class of medications, PARP inhibitors, in treating metastatic castrate-resistant prostate cancer patients with alterations within BRCA and ATM genes. …
